WooGene B&G Co., Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 11, 2022 at 06:36 am
Share
WooGene B&G Co., Ltd reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported negative sales was KRW 0.00001 million. Net income was KRW 56.39 million compared to net loss of KRW 38.18 million a year ago. Basic earnings per share from continuing operations was KRW 2 compared to basic loss per share from continuing operations of KRW 1 a year ago. Diluted earnings per share from continuing operations was KRW 2 compared to diluted loss per share from continuing operations of KRW 1 a year ago. Basic earnings per share was KRW 2 compared to basic loss per share of KRW 1 a year ago.
For the nine months, net income was KRW 321.13 million compared to net loss of KRW 585.85 million a year ago. Basic earnings per share from continuing operations was KRW 11 compared to basic loss per share from continuing operations of KRW 20 a year ago. Diluted earnings per share from continuing operations was KRW 11 compared to diluted loss per share from continuing operations of KRW 20 a year ago. Basic earnings per share was KRW 11 compared to basic loss per share of KRW 20 a year ago.
WooGene B&G Co., Ltd. is a Korea-based company mainly engaged in the manufacture of veterinary drugs. The Companyâs products include anti-infective, bulk materials, probiotics, enzymes, antiparasitics, hormone preparations, vaccines, aquacultures, anesthetics, teat dips, disinfectants, pet cure drugs, calcium injections, antiphlogistic injections, enhance metabolism injections, diarrhea remedy injections, sedative injections for swine, toxin binders, pigmentation drugs and others. The Company also provides anti-inflammatory enzymes under the brand name SKD, which are used for human beings. The Company distributes its products within domestic market and to overseas markets, including Iran, Vietnam, Philippines, Brazil and others.